Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Other Non-Current Liabilities (2022 - 2025)

Senti Biosciences has reported Other Non-Current Liabilities over the past 4 years, most recently at $8.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 60.41% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 60.41%, while the annual FY2025 figure was $8.1 million, 60.41% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $8.1 million at Senti Biosciences, up from $7.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $8.1 million in Q4 2025 and troughed at $20000.0 in Q2 2023.
  • A 4-year average of $3.1 million and a median of $1.6 million in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 97.53% in 2023 and later soared 32695.0% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $227000.0 in 2022, then skyrocketed by 1670.93% to $4.0 million in 2023, then increased by 25.6% to $5.0 million in 2024, then soared by 60.41% to $8.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SNTI at $8.1 million in Q4 2025, $7.6 million in Q3 2025, and $7.6 million in Q2 2025.